Halozyme Therapeutics to Acquire Elektrofi, Inc.
October 1, 2025
Halozyme Therapeutics (NASDAQ: HALO) entered into a definitive agreement to acquire Elektrofi, a biopharmaceutical formulation technology company developing Hypercon, an ultra-high concentration microparticle technology for biologics. The deal includes an upfront payment of $750 million plus up to three $50 million regulatory milestone payments, and is expected to close in the fourth quarter of 2025 subject to HSR review and customary closing conditions.
- Buyers
- Halozyme Therapeutics, Inc.
- Targets
- Elektrofi, Inc.
- Industry
- Biotechnology
- Location
- United States
- Transaction Type
- Buyout
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.